Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Robinia pseudoacacia pollen is a biologic allergenic extract derived from the pollen of the black locust tree (Robinia pseudoacacia). It is utilized as a diagnostic agent for in vivo allergy testing, such as skin prick tests, to identify hypersensitivity to this specific pollen in individuals with pollinosis. [1] The mechanism of diagnosis involves introducing the extract into the skin, which in sensitized individuals, triggers a localized IgE-mediated immune response, manifesting as a wheal and flare. The allergenic profile of Robinia pseudoacacia pollen includes several panallergens, notably profilin, a calcium-binding protein (polcalcin), and 1,3-beta-glucanase, which can lead to cross-reactivity with other pollens. [1, 2] The substance is registered in DrugBank under the accession number DB10474. [3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Robinia pseudoacacia pollen.